CFGS
ACAD icon

Concourse Financial Group Securities’s Acadia Pharmaceuticals ACAD Stock Holding History

Concourse Financial Group Securities’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-100
Closed -$2.72K – 2302
2023
Q2 		$2.4K Hold
100
– – ﹤0.01% 1984
2023
Q1 		$1.88K Hold
100
– – ﹤0.01% 2068
2022
Q4 		$1.59K Buy
+100
New +$1.56K ﹤0.01% 2078
2022
Q3 		– Sell
-100
Closed -$1.62K – 1983
2022
Q2 		$1K Hold
100
– – ﹤0.01% 2075
2022
Q1 		$2K Hold
100
– – ﹤0.01% 1989
2021
Q4 		$2K Hold
100
– – ﹤0.01% 2173
2021
Q3 		$2K Hold
100
– – ﹤0.01% 2201
2021
Q2 		$2K Sell
100
-100
-50% -$2.26K ﹤0.01% 2161
2021
Q1 		$5K Sell
200
-100
-33% -$4.4K ﹤0.01% 1949
2020
Q4 		$16K Buy
+300
New +$14.9K ﹤0.01% 1531
2020
Q3 		– Sell
-495
Closed -$21.4K – 2148
2020
Q2 		$24K Sell
495
-220
-31% -$10.6K ﹤0.01% 1228
2020
Q1 		$30K Buy
+715
New +$29.5K ﹤0.01% 1087
2019
Q1 		– Sell
-128
Closed -$2.99K – 2246
2018
Q4 		$2K Buy
128
+11
+9% +$214 ﹤0.01% 1879
2018
Q3 		$2K Buy
+117
New +$1.84K ﹤0.01% 1551

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Concourse Financial Group Securities's ACAD Position: Q3 2023 in Review

Concourse Financial Group Securities sold out of Acadia Pharmaceuticals (ACAD) in Q3 2023, closing a stake of 100 shares — an estimated $2.72K sold.

Concourse Financial Group Securities first reported a position in ACAD in Q3 2018 and held it in 14 quarters. The position peaked at $30K in Q1 2020. 248 funds tracked by Wall St. Rank hold ACAD as of Q3 2023.

  • Concourse Financial Group Securities reported no remaining Acadia Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Concourse Financial Group Securities sold 100 Acadia Pharmaceuticals shares in Q3 2023, an estimated $2.72K.
  • Concourse Financial Group Securities first reported a position in Acadia Pharmaceuticals in Q3 2018 and held it in 14 quarters.
  • Concourse Financial Group Securities's Acadia Pharmaceuticals position peaked at $30K in Q1 2020.
  • 248 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2023.

Based on Concourse Financial Group Securities's 13F filing for Q3 2023, filed 25 Oct 2023.